The global insulin market is projected to grow from US$ 18.5 billion in 2021 to US$ 30 billion by the end of 2031, with a CAGR of 4.3% from 2022 to 2031. The growth is driven by several factors, ...
Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...
Long-Acting Insulin Analogs Dominate the Global Biosimilar Market, While Rapid-Acting Insulins Lead in Growth Potential ...
The FTC filed a lawsuit in September, accusing the three major PBMs of anticompetitive rebating practices related to insulin.
Similarly, Express Scripts’ 2024 National Preferred Formulary appears to prioritize higher list price versions of Tresiba and Semglee, leaving out the more affordable versions. Optum Rx’s 2023 ...
Biocon Biologic’s Semglee (insulin glargine-yfgn) and an unbranded product launched in November 2021. At the time, they were the first interchangeable biosimilars to Lantus. Since then, a second ...
Mylan and Biocon Biologics’ Semglee was the first insulin product deemed a biologic under section 351(a) per the Biologics Price Competition and Innovation Act (BPCIA) and is now under review ...
After hours: 7:00:36 p.m. EST Loading Chart for VTRS ...
Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...